Mujaro, anti-obesity injections, allows you to lose weight for at least three years
The pharmaceutical company Lilly presented the results of Munjaro’s clinical trial, the longest to date, for three years, weekly injections demonstrating high effectiveness against obesity and diabetes, along with the drugs Ozempic and Wegoby. A study published in the New England Journal of Medicine, a journal that publishes findings that may change clinical practice, demonstrates that Munjaro reduces the risk of progression type 2 diabetes in adults with prediabetes and obesity and overweightfor 176 weeks.
In particular, according to a new study, Lilly injections containing tirzepatide caused weight loss sustained average of 22.9% over three years. “Patients treated with tirzepatide lost an average of up to 23% of their body weight and maintained it for more than three years. This result combines evidence of effectiveness and sustainability over time. unprecedented in pharmacological intervention for obesity. Only bariatric surgery“It is clear that, with different costs and risks, we achieved similar results,” says Dr. Fernando Gómez Peralta, coordinator of the diabetes knowledge area of the Spanish Society of Endocrinology and Nutrition (SEEN).
This Thursday marks World Diabetes Day, which… type 2 This is associated with obesity. “Without this risk factor, 70% of cases diagnosed with type 2 would not exist,” says Antonio Perez, director of the endocrinology department of the Santa Creu e Sant Pau Hospital in Barcelona and president of the Foundation Spanish Diabetes Society (FSED).
Muñaro arrived in Spain in July last year and has been approved to treat the disease as it helps regulate blood levels. glucose. It is administered using injection under the skin once a week. Tirzepatide, unlike the famous Ozempic, has a dual mechanism of action, since it acts on the GIP and GLP-1 receptors, which play an important role in appetite regulation and glucose metabolism. Ozempic, considered a 2023 breakthrough by Science, only targets the GLP-1 hormone, so some studies suggest Mujaro may have a greater effect on appetite reduction.
Effect on diabetes
It also has a “tremendous clinical impact” in preventing diabetesas emphasized by Dr. Gómez Peralta. And 99% of people treated with tirzepatide and study participants were free of diabetes after 176 weeks. “The risk of developing type 2 diabetes in this high-risk group risk decreased by 90% compared to the control group,” said the specialist.
Similarly, a pharmaceutical company reports that the profile safety and tolerability Tirzepatide at 193 weeks (176 weeks plus 17 weeks without treatment) is comparable to previously published results from a 72-week study. Apart from Covid, the most common adverse events were gastrointestinal tract and generally “mild to moderate severity.” The most common gastrointestinal adverse events were nausea, diarrhea and constipation.